Duration of Anti-PD-1 Therapy in Metastatic Melanoma

The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.

Trial Details

NCT ID
NCT02821013
Phase
PHASE3
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Intermittent PD-1 inhibitor therapy
  • Continuous PD-1 inhibitor therapy
Locations (sample)
  • Victoria, Mildura, Australia
  • Coffs Harbour, New South Wales, Australia|-30.29626,153.11351
  • Waratah, New South Wales, Australia|-32.90667,151.72647
  • Westmead, New South Wales, Australia|-33.80383,150.98768
  • Birtinya, Queensland, Australia|-26.74322,153.11913

Key Eligibility Criteria

  • Histologically confirmed melanoma that is unresectable / metastatic (stage III or stage IV).
  • Eligible to receive treatment with a government approved and publically-funded PD-1 inhibitor, according to the guidance / indications described in…
  • Patients must have evidence of unresectable / metastatic disease, that is considered evaluable by the investigator and can be followed, but measura…
  • Patients with brain metastases are allowed, provided they are stable according to the following definitions:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →